Pfizer Rebuilds Commercial Model Around Acquired Products and Vaccines
What happened
Pfizer is rebuilding its commercial model around newer and acquired products while decreasing its dependence on its COVID-19 franchise. The company has redirected spending toward markets and products expected to generate stronger returns. New and acquired products produced $4 billion globally in the second quarter, and Pfizer has cut operating expenses and halted certain less productive launches and clinical studies.
From themarketsdaily.com
Why it matters
The strategic pivot indicates a move away from the declining revenue of COVID-19 products. Pfizer is increasing its reliance on products acquired or launched recently, such as those related to older-adult vaccines. This restructuring aims to generate stronger returns and improve sales-force productivity.
From themarketsdaily.com
Who's involved
- PfizerIs rebuilding its commercial model and reducing exposure to its COVID-19 franchise.
- SeagenWas acquired by Pfizer and integrated to bolster its portfolio.
- Albert BourlaServes as the CEO and Chairman of Pfizer, directing its strategy.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Morgan StanleySpeculative
Morgan Stanley might adjust investment ratings due to Pfizer's strategic refocusing and growth in key markets.